FGF-23/vitamin D axis in type 1 diabetes: The potential role of mineral metabolism in arterial stiffness

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Llauradó, Gemma ^a,b,d   Megia, Ana ^a,d   Cano, Albert ^c   Giménez Palop, Olga ^c   Simón, Inmaculada ^a,d   González Sastre, Montserrat ^c   Berlanga, Eugenio ^c   Fernández Veledo, Sonia ^a,d   Vendrell, Joan ^a,d   González Clemente, José Miguel ^c,d  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR 23; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPID; PARATHYROID HORMONE; PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VITAMIN D; 25-HYDROXYVITAMIN D; FIBROBLAST GROWTH FACTOR; MINERAL;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MINERAL METABOLISM; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; PULSE WAVE; SMOKING; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; METABOLISM; PATHOPHYSIOLOGY;

ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MINERALS; PULSE WAVE ANALYSIS; VASCULAR STIFFNESS; VITAMIN D;

EID: 84948822906     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140222     Document Type: Article

References (41)

1. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 2005 111: 3489-3493. PMID: 15983263
2. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 2001 37: 1053-1059. PMID: 11304502
3. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008 168: 1629-1637. doi: 10.1001/archinte.168.15.1629 PMID: 18695076
4. Joergensen C, Gall MA, Schmedes A, Tarnow L, Parving HH, Rossing P. Vitamin D levels and mortality in type 2 diabetes. Diabetes Care 2010 33: 2238-2243. doi: 10.2337/dc10-0582 PMID: 20606205
5. Joergensen C, Hovind P, Schmedes A, Parving HH, Rossing P. Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. Diabetes Care 2011 34: 1081-1085. doi: 10.2337/dc10- 2459 PMID: 21525501
6. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators-A critical appraisal. Cell Metab 2012 16: 693-705. doi: 10.1016/j.cmet.2012.11.001 PMID: 23217254
7. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003 64: 2272-2279. PMID: 14633152
8. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007 18: 2600-2608. PMID: 17656479
9. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008 359: 584-592. doi: 10. 1056/NEJMoa0706130 PMID: 18687639
10. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011 305: 2432-2439. doi: 10.1001/jama.2011.826 PMID: 21673295
11. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012 60: 200-207. doi: 10.1016/j.jacc.2012.03.040 PMID: 22703926
12. Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013 8: 781-786. doi: 10.2215/CJN.09570912 PMID: 23335040
13. Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al. Higher fibroblast growth factor- 23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013 83: 160-166. doi: 10.1038/ki.2012.327 PMID: 22951890
14. Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutierrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One 2015 10: E0122885. doi: 10.1371/journal.pone.0122885 PMID: 25811862
15. Llaurado G, Ceperuelo-Mallafre V, Vilardell C, Simo R, Freixenet N, Vendrell J, et al. Arterial stiffness is increased in patients with type 1 diabetes without cardiovascular disease: A potential role of low-grade inflammation. Diabetes Care 2012 35: 1083-1089. doi: 10.2337/dc11-1475 PMID: 22357186
16. de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: A scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 2014 37: 2843-2863. doi: 10.2337/dc14-1720 PMID: 25114297
17. Hallal PC, Victora CG. Reliability and validity of the International Physical Activity Questionnaire (IPAQ). Med Sci Sports Exerc 2004 36: 556. PMID: 15076800
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009 150: 604-612. PMID: 19414839
19. Llaurado G, Ceperuelo-Mallafre V, Vilardell C, Simo R, Albert L, Berlanga E, et al. Impaired endothelial function is not associated with arterial stiffness in adults with type 1 diabetes. Diabetes Metab 2013 39: 355-362. PMID: 23643350
20. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: Current understanding and future directions. J Am Coll Cardiol 2011 57: 1511-1522. doi: 10.1016/j.jacc.2010.12.017 PMID: 21453829
21. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol 2010 55: 1318-1327. doi: 10.1016/j.jacc.2009.10.061 PMID: 20338492
22. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J 2006 27: 2588-2605. PMID: 17000623
23. Reyes-Garcia R, Garcia-Martin A, Garcia-Fontana B, Morales-Santana S, Rozas-Moreno P, Munoz- Torres M. FGF23 in type 2 diabetic patients: Relationship with bone metabolism and vascular disease. Diabetes Care 2014 37: E89-90. doi: 10.2337/dc13-2235 PMID: 24757249
24. Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol 2012 7: 727-734. doi: 10.2215/CJN.10331011 PMID: 22383747
25. Semba RD, Fink JC, Sun K, Cappola AR, Dalal M, Crasto C, et al. Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol 2012 7: 85-91. doi: 10.2215/CJN.08070811 PMID: 22076875
26. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 15: 2208-2218. PMID: 15284307
27. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011 121: 4393-4408. doi: 10.1172/JCI46122 PMID: 21985788
28. Saito Y, Yamagishi T, Nakamura T, Ohyama Y, Aizawa H, Suga T, et al. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 1998 248: 324-329. PMID: 9675134
29. Olauson H, Vervloet MG, Cozzolino M, Massy ZA, Urena Torres P, Larsson TE. New insights into the FGF23-Klotho axis. Semin Nephrol 2014 34: 586-597. doi: 10.1016/j.semnephrol.2014.09.005 PMID: 25498378
30. Nakayama M, Kaizu Y, Nagata M, Ura Y, Ikeda H, Shimamoto S, et al. Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: A cross-sectional study. BMC Nephrol 2013 14: 22. doi: 10.1186/1471-2369-14-22 PMID: 23339433
31. Balci M, Kirkpantur A, Gulbay M, Gurbuz OA Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int 2010 14: 425-432. doi: 10.1111/j.1542-4758.2010.00480.x PMID: 20955275
32. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010 25: 2679-2685. doi: 10.1093/ndt/gfq089 PMID: 20176609
33. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011 22: 124-136. doi: 10.1681/ASN. 2009121311 PMID: 21115613
34. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005 25: 932-943. PMID: 15731494
35. Reis JP, von Muhlen D, Miller ER 3rd, Michos ED, Appel LJ. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics 2009 124: E371-379. doi: 10.1542/peds. 2009-0213 PMID: 19661053
36. Pozzilli P, Manfrini S, Crino A, Picardi A, Leomanni C, Cherubini V, et al. Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. Horm Metab Res 2005 37: 680-683. PMID: 16308836
37. Littorin B, Blom P, Scholin A, Arnqvist HJ, Blohme G, Bolinder J, et al. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: Results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 2006 49: 2847-2852. PMID: 17072585
38. Bierschenk L, Alexander J, Wasserfall C, Haller M, Schatz D, Atkinson M. Vitamin D levels in subjects with and without type 1 diabetes residing in a solar rich environment. Diabetes Care 2009 32: 1977-1979. doi: 10.2337/dc09-1089 PMID: 19675194
39. Young KA, Snell-Bergeon JK, Naik RG, Hokanson JE, Tarullo D, Gottlieb PA, et al. Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes. Diabetes Care 2011 34: 454-458. doi: 10.2337/dc10-0757 PMID: 20978098
40. Sachs MC, Brunzell JD, Cleary PA, Hoofnagle AN, Lachin JM, Molitch ME, et al. Circulating vitamin D metabolites and subclinical atherosclerosis in type 1 diabetes. Diabetes Care 2013 36: 2423-2429. doi: 10.2337/dc12-2020 PMID: 23530012
41. Lieberman R, Wadwa RP, Nguyen N, Bishop FK, Reinick C, Snell-Bergeon JK, et al. The association between vitamin D and vascular stiffness in adolescents with and without type 1 diabetes. PLoS One 2013 8: E77272. doi: 10.1371/journal.pone.0077272 PMID: 24204786